Wedbush analyst Liana Moussatos said the sell-off in Regulus Therapeutics (NASDAQ: RGLS) is overdone. The firm reiterated an ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE